Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Which has more volatility and risk, SUPN or JAZZ?

Supernus Pharmaceuticals has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.

Do analysts prefer SUPN or JAZZ?

Supernus Pharmaceuticals presently has a consensus target price of $36.00, indicating a potential upside of 12.52%. Jazz Pharmaceuticals has a consensus target price of $184.00, indicating a potential upside of 68.12%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.92

Do institutionals & insiders have more ownership in SUPN or JAZZ?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media favor SUPN or JAZZ?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 11 mentions for Jazz Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.90 beat Supernus Pharmaceuticals' score of 0.81 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SUPN or JAZZ more profitable?

Jazz Pharmaceuticals has a net margin of 11.86% compared to Supernus Pharmaceuticals' net margin of 9.27%. Jazz Pharmaceuticals' return on equity of 26.62% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	9.27%	12.23%	9.17%
Jazz Pharmaceuticals	11.86%	26.62%	9.14%

Which has higher earnings and valuation, SUPN or JAZZ?

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$661.82M	2.71	$73.86M	$1.11	28.82
Jazz Pharmaceuticals	$4.07B	1.63	$560.12M	$7.50	14.59

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.